Zelira Therapeutics Limited
Zelira Therapeutics Limited, a biopharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based medicines for the treatment of various medical conditions in Australia and the United States. It offers formulations under the HOPE brand in Australia, Washington, Pennsylvania, and Louisiana, as well as develops ZENIVOL, a cannabinoid drug for the treatment o… Read more
Zelira Therapeutics Limited (ZLDAF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2023: -0.057x
Based on the latest financial reports, Zelira Therapeutics Limited (ZLDAF) has a cash flow conversion efficiency ratio of -0.057x as of June 2023.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.82 Million) by net assets ($31.71 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Zelira Therapeutics Limited - Cash Flow Conversion Efficiency Trend (2015–2023)
This chart illustrates how Zelira Therapeutics Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Zelira Therapeutics Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Zelira Therapeutics Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Rich Goldman Holdings Limited
F:MRU3
|
-0.033x |
|
Longhorn Exploration Corp
V:LEX
|
-0.077x |
|
Hammer Fiber Optics Holdings Corp
PINK:HMMR
|
0.230x |
|
Yaprak Sut ve Besi Ciftlikleri Sanayi ve Ticaret AS
IS:YAPRK
|
-0.042x |
|
Painreform Ltd
NASDAQ:PRFX
|
-0.117x |
|
TinOne Resources Inc.
OTCQB:TORCF
|
-0.045x |
|
23B
F:23B
|
-0.002x |
|
Interactive Strength Inc. Common Stock
NASDAQ:TRNR
|
-0.139x |
Annual Cash Flow Conversion Efficiency for Zelira Therapeutics Limited (2015–2023)
The table below shows the annual cash flow conversion efficiency of Zelira Therapeutics Limited from 2015 to 2023.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-06-30 | $31.71 Million | $-7.25 Million | -0.229x | +13.46% |
| 2022-06-30 | $35.69 Million | $-9.43 Million | -0.264x | -15.97% |
| 2021-06-30 | $37.83 Million | $-8.62 Million | -0.228x | -13.45% |
| 2020-06-30 | $34.55 Million | $-6.94 Million | -0.201x | +81.34% |
| 2019-06-30 | $3.11 Million | $-3.34 Million | -1.076x | -154.74% |
| 2018-06-30 | $6.21 Million | $-2.62 Million | -0.422x | -51.54% |
| 2017-06-30 | $7.90 Million | $-2.20 Million | -0.279x | -116.96% |
| 2016-06-30 | $-202.91K | $-333.52K | 1.644x | +300.84% |
| 2015-06-30 | $275.06K | $-225.12K | -0.818x | -- |